Protein–protein interactions (PPIs) execute many fundamental cellular functions and have
served as prime drug targets over the last two decades. Interfering intracellular PPIs with …

The transcription factor nuclear factor erythroid 2‐related factor 2 (NRF2) is considered the
master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective …

Protein-protein interactions (PPIs) are well-established as a class of promising drug targets
for their implications in a wide range of biological processes. However, drug development …

Developing macrocyclic peptides that can reach intracellular targets is a significant
challenge. This review discusses the most recent strategies used to develop cell permeable …

In the last two decades, protein–protein interactions (PPIs) have been used as the main
target for drug development. However, with larger or superficial binding sites, it has been …

The accurate prediction of protein structures achieved by deep learning (DL) methods is a
significant milestone and has deeply impacted structural biology. Shortly after its release …

Highlights•Structure-based strategies allow more-specific targeting of protein–protein
interactions (PPIs).•Interfering peptides (IPs) become a promising alternative to small …

Large contact surfaces of protein–protein interactions (PPIs) remain to be an ongoing issue
in the discovery and design of small molecule modulators. Peptides are intrinsically capable …

Introduction: There are currently no specific drugs and universal vaccines for Coronavirus
disease 2019 (COVID-19), hence urgent effective measures are needed to discover and …

Protein complexes are defined by the three‐dimensional structure of participating binding
partners. Knowledge about these structures can facilitate the design of peptidomimetics …